Boni Maxime Ale1, Franck Amahowe2, Motto Malea Nganda3, Célestin Danwang4, Nelly Njeri Wakaba2, Ateeq Almuwallad5,6, Franck Biaou Guy Ale2, Alamou Sanoussi7, Suleiman Hudu Abdullahi8, Jean Joel Bigna9. 1. Holo Healthcare Limited, Nairobi, Kenya. boniale@holo-healthcare.com. 2. Holo Healthcare Limited, Nairobi, Kenya. 3. Department of Clinical Science and International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK. 4. Epidemiology and Biostatistics Unit, Institute of Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium. 5. Applied Medical Sciences College, Jazan University, Jazan, Saudi Arabia. 6. Center for Trauma Science, Queen Mary University of London, London, UK. 7. Transition Support Program Department, Advocate Good Samaritan Hospital, Downers Grove, IL, USA. 8. Leprosy and Tuberculosis Relief Initiative Nigeria, Plateau, Nigeria. 9. Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé, Cameroon.
Abstract
BACKGROUND: Although the high burden of both active smoking and human immunodeficiency virus (HIV) is clearly known, the relationship between them is still not well characterized. Therefore, we estimated the global prevalence of active smoking in people living with HIV (PLHIV) on antiretroviral therapy (ART) and investigated the association between exposure to active smoking and risk for suboptimal adherence to ART. Main text: We searched PubMed, Embase, and Web of Science to identify articles published until September 19, 2019. Eligible studies reported the prevalence of active smoking in PLHIV on ART or investigated the association between active smoking and ART adherence; or enough data to compute these estimates. We used a random-effects model to pool data and quantified heterogeneity (I2). The global prevalence of active smoking was 36.1% (95% CI: 33.7-37.2; 329 prevalence data; 462 104 participants) with substantial heterogeneity. The prevalence increased with level of country income; from 10.1% (95% CI: 6.8-14.1) in low-income to 45.2% (95% CI: 42.7-47.7) in high-income countries; P < 0.0001. With regards to the Joint United Nations Programme on HIV/AIDS (UNAIDS) regions, the prevalence was higher in West and Central Europe and North America 45.4% (42.7-48.1) and lowest in the two UNAIDS regions of sub-Saharan Africa: Eastern and Southern Africa 10.7% (95% CI: 7.8-14.0) and West and Central Africa 4.4% (2.9-6.3); P < 0.0001. Globally, we estimated that there were 4 110 669 PLHIV on ART who were active smokers, among which the highest number was from Eastern and Southern Africa (35.9%) followed by Asia and the Pacific (25.9%). Active smoking was significantly associated with suboptimal ART adherence: pooled odds ratio 1.57 (95% CI: 1.37-1.80; I2 = 56.8%; 19 studies; 48 450 participants); even after considering adjusted estimates: 1.67 (95% CI: 1.39-2.01; I2 = 53.0%; 14 studies). CONCLUSIONS: This study suggests a high prevalence of active smoking in PLHIV on ART and an association between active smoking and ART suboptimal adherence. As such, healthcare providers and policy makers should focus on adopting and implementing tobacco harm reduction strategies in HIV care, especially in sub-Saharan Africa known as epicenter of HIV pandemic with highest number of active tobacco smoking among PLHIV on ART.
BACKGROUND: Although the high burden of both active smoking and human immunodeficiency virus (HIV) is clearly known, the relationship between them is still not well characterized. Therefore, we estimated the global prevalence of active smoking in people living with HIV (PLHIV) on antiretroviral therapy (ART) and investigated the association between exposure to active smoking and risk for suboptimal adherence to ART. Main text: We searched PubMed, Embase, and Web of Science to identify articles published until September 19, 2019. Eligible studies reported the prevalence of active smoking in PLHIV on ART or investigated the association between active smoking and ART adherence; or enough data to compute these estimates. We used a random-effects model to pool data and quantified heterogeneity (I2). The global prevalence of active smoking was 36.1% (95% CI: 33.7-37.2; 329 prevalence data; 462 104 participants) with substantial heterogeneity. The prevalence increased with level of country income; from 10.1% (95% CI: 6.8-14.1) in low-income to 45.2% (95% CI: 42.7-47.7) in high-income countries; P < 0.0001. With regards to the Joint United Nations Programme on HIV/AIDS (UNAIDS) regions, the prevalence was higher in West and Central Europe and North America 45.4% (42.7-48.1) and lowest in the two UNAIDS regions of sub-Saharan Africa: Eastern and Southern Africa 10.7% (95% CI: 7.8-14.0) and West and Central Africa 4.4% (2.9-6.3); P < 0.0001. Globally, we estimated that there were 4 110 669 PLHIV on ART who were active smokers, among which the highest number was from Eastern and Southern Africa (35.9%) followed by Asia and the Pacific (25.9%). Active smoking was significantly associated with suboptimal ART adherence: pooled odds ratio 1.57 (95% CI: 1.37-1.80; I2 = 56.8%; 19 studies; 48 450 participants); even after considering adjusted estimates: 1.67 (95% CI: 1.39-2.01; I2 = 53.0%; 14 studies). CONCLUSIONS: This study suggests a high prevalence of active smoking in PLHIV on ART and an association between active smoking and ART suboptimal adherence. As such, healthcare providers and policy makers should focus on adopting and implementing tobacco harm reduction strategies in HIV care, especially in sub-Saharan Africa known as epicenter of HIV pandemic with highest number of active tobacco smoking among PLHIV on ART.
Entities:
Keywords:
AIDS; Antiretroviral therapy; Global health; HIV; Smoking; Tobacco
Authors: Ewoud Schuit; Orestis A Panagiotou; Marcus R Munafò; Derrick A Bennett; Andrew W Bergen; Sean P David Journal: Cochrane Database Syst Rev Date: 2017-09-08
Authors: Regina El Dib; Erica A Suzumura; Elie A Akl; Huda Gomaa; Arnav Agarwal; Yaping Chang; Manya Prasad; Vahid Ashoorion; Diane Heels-Ansdell; Wasim Maziak; Gordon Guyatt Journal: BMJ Open Date: 2017-02-23 Impact factor: 2.692
Authors: Jonathan Shuter; Krishna P Reddy; Emily P Hyle; Cassandra A Stanton; Nancy A Rigotti Journal: Lancet HIV Date: 2021-08-27 Impact factor: 16.070
Authors: Krysten W Bold; Yanhong Deng; James Dziura; Elizabeth Porter; Keith M Sigel; Jessica E Yager; David M Ledgerwood; Steven L Bernstein; E Jennifer Edelman Journal: Transl Behav Med Date: 2022-07-07 Impact factor: 3.626
Authors: Janet Diaz-Martinez; Ivan Delgado-Enciso; Adriana Campa; Javier A Tamargo; Haley R Martin; Angelique Johnson; Suzanne Siminski; Pamina M Gorbach; Marianna K Baum Journal: Int J Environ Res Public Health Date: 2022-07-05 Impact factor: 4.614